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P A T E N T  W A T C H  
Drug patenting in India: looking back and 
looking forward 
Patent protection for drugs in India has been a contentious issue in recent years, with several high-profile denials of patents; for 
example, for Novartis’s anticancer drug imatinib mesylate (Glivec). Much of the debate around pharmaceutical patenting in India has 
focused on a particular provision— Section 3(d) — of the Indian Patent Act, which was introduced in 2005 as part of India’s 
implementation of the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 
2005. It has been argued that 3(d) makes it difficult to obtain patents for new drugs in India (Health Affairs 33: 1567–1575; 2014, and 
Special 301 Report; 2015 (Further Information)), which has led to numerous calls to overturn or rethink this provision. Here, 
however, we argue that the attention paid to Section 3(d) may be misleading and that another element of India’s TRIPS 
implementation may be more relevant to the current pharmaceutical patenting landscape in India. 
TRIPS, which entered into effect in 1995, required countries to grant pharmaceutical product patents. Prior to this time few 
developing countries did so. In complying with TRIPS, India took steps aimed to ameliorate the feared effects of pharmaceutical 
patenting on access to medicines, such as the inclusion of Section 3(d), which aims to curb the granting of patents to new forms, 
compositions, and uses of existing substances — so-called ‘secondary patents’. Secondary patents are legally more vulnerable, not 
only in India but globally. For example, in the USA most secondary patents are overturned when litigated to completion (Science 339: 
1386–1387; 2013). Indeed in the case of Glivec, the secondary patent was the subject of a US patent challenge (Science 337: 414–
415; 2012). 
While 3(d) has attracted considerable attention, another, aspect of India’s TRIPS implementation was to disallow any patents with 
priority years (year of first global filing) before 1995. During the TRIPS negotiations, pharmaceutical companies lobbied to make 
patent protection on pre-1995 molecules mandatory, arguing that not doing so would substantially delay the commercial benefits from 
TRIPS (Patent World 75: 29–33; 1995). These attempts failed. 
How important is the 1995 cut-off date? Assuming that the earliest patent for a drug is its compound patent, the majority of the  
430 drugs with patents approved by the US Food and Drug Administration (FDA) between 1995 and 2013 had their first patent 
filing dates before 1995 (FIG. 1, top panel). Even among drugs approved since 2010,, nearly a quarter (23.7%) had their first patents 
filed before 1995 (FIG. 1, bottom panel).. Of the 23 of these drugs that ranked among the top top 50 drugs by 2012 US sales, 20 had 
pre-1995 priority dates  (Supplementary information S1 (table)). Pre-1995 compound patents are not eligible for protection in India, 
regardless of Section 3(d) or any other features of the post-2005 Indian pharmaceutical patent system.  
Drugs with pre-1995 primary patents must rely on ‘weaker’ secondary patents as their only form of protection in India, as 
illustrated by the Glivec case. Novartis’ compound patent had a priority date of 1992 (Figure 1), so was not eligible for protection in 
India. Its application for a secondary patent, covering a crystalline form of the 1992 compound, was rejected in India, on 3(d) and 
other grounds. As a result Novartis was left with no patent protection at all in India for Glivec. 
The outcome in the Glivec case has been interpreted as evidence that 3(d) makes patenting in India too hard—if even a drug like 
Glivec is unable to obtain patent protection in India, something must be wrong with 3(d). However, the case also illustrates the 
interaction of 3(d) with the initial policy choice to make pre-1995 molecules ineligible for patents. As 1995 recedes further into the 
past, drugs with post-1995 compound patents will become typical. As 3(d) mainly focuses on secondary patents, we expect these 
drugs to obtain patent protection in India. There are exceptions: drugs without compound patents anywhere, and drugs whose 
compound patents can be construed as derivative and therefore vulnerable to 3(d). However, most new molecular entities have 
compound patents (Journal of Health Economics 31: 327–339; 2012), and showing that a compound patent is derivative is difficult. 
Of note, this seems to be the basis of the Indian Patent Office’s recent rejection – currently under appeal – of the patent application on 
sofosbuvir (Sovaldi), Gilead’s new Hepatitis C treatment. 
The various aspects of TRIPS implementation are interdependent in ways that matter for the future of drug patenting in India. For 
drugs with pre-1995 compound patents that are not eligible in India, Section 3(d) and other restrictions on secondary patenting may 
determine whether a drug gets any patent protection at all. For drugs with post-1995 compounds that are likely to be patented in India, 
the main effects of 3(d), and other restrictions on secondary patents will be on the duration of protection. 
The difference between an explanation for rates of pharmaceutical patenting based on 3(d) versus one based on timing is that the 
effects of the latter are temporary. We anticipate that if 3(d) is implemented as intended, to limit secondary patents, then as 1995 fades 
further into the past most new molecular entities will get one patent in India, but only one. Whether this is enough protection to 
balance innovation and access we cannot say. However, 3(d) will not necessarily make India a patent-free zone. 
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Figure 1 | Earliest priority year and approval year for patented new molecular entities approved in the USA between 1995 and 2013. This 
figure plots the priority year (year in which the first patent on a drug had its first global patent application) and year of approval by the 
US Food and Drug Administration (FDA) for all patented new molecular entities approved by the FDA between 1995 and 2003. The 
first panel shows priority year versus approval year, with marker size proportional to the number of drugs approved with specific 
priority and approval year. The second panel shows the share of drug approvals with pre-1995 priority. If we assume the first patent 
on a drug is its compound patent, drugs with per-1995 priority must rely on secondary patents for protection in India. See 
Supplementary information S1 (table) for details. 
 
FURTHER INFORMATION 
United States Trade Representative. Special 301 Report 2015: https://ustr.gov/sites/default/files/2015-Special-301-Report-FINAL.pdf 
SUPPLEMENTARY INFORMATION 
See online article: S1 (table) 
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Four drugs approved in 2001, including Glivec, have a priority year of 1992
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Supplementary Table 
Priority and approval year of drugs approved 1995-2012 that were among the top 50 selling 
drugs in 2012 
 
Sales Rank  Product Drug approval year Priority year of first patent 
2 Abilify 2002 1978 
3 Crestor 2003 1991 
5 Cymbalta 2004 1986 
9 Copaxone 1996 1994 
11 Singulair 1998 1990 
13 Plavix 1997 1982 
17 Januvia 2006 1996 
19 Lantus 2000 1988 
23 Diovan 1996 1990 
24 Lyrica 2004 1990 
25 Lipitor 1996 1986 
26 Celebrex 1998 1993 
28 Gleevec 2001 1992 
29 Namenda 2003 1989 
30 Actos 1999 1978 
33 Vyvanse 2007 2002 
35 Seroquel 1997 1986 
36 Zetia 2002 1993 
39 Incivek 2011 2000 
45 Novolog 2000 1985 
48 Alimta 2004 1989 
49 Eloxatin 2002 1992 
50 Levemir 2005 1993 
        
Notes:       
Sales data from http://www.pharmacytimes.com/publications/issue/2013/July2013/Top-200-
Drugs-of-2012 
Shading indicates pre-1995 priority    
        
 
 
Supplementary Information 
Constructing a list of all new molecular entity (NME) drug approvals between 1995 and 2013 
We began with the April 2014 version of the U.S. Food and Drug Administration’s 
“Drugs@FDA” database [1]. Using APPLICATION.TXT we determined which 
applications were new drug applications (appltype=N) and which where for new molecular 
entities (chemical_type=1). Using REGACTIONDATE.TXT we determined the first 
approval year for each new drug application. Using PRODUCT.TXT we determined the 
drug name for the first product (productno=1) associated with each new drug application. 
We began our analysis with the 486 new molecular entities, hereafter “drugs,” approved 
between 1995 and 2013. 
Constructing patent information for each drug 
For each of these drugs we then obtained data from the FDA’s Orange Book on all 
associated patents. Because some of the patents on earlier drugs will have expired, and thus 
no longer be recorded in the current Orange Book, we relied on a dataset of all patents listed 
in the Orange Book from 1985-2012 [2]. Since our sample extends to 2013 drug approvals, 
we supplemented this with information from the October 2014 Electronic Version of the 
Orange Book [3]. We dropped from this set one patent (1712251, on “Manufacture of 
rolled-steel members”) which appears to have been an Orange Book listing mistake. 
There were 1776 distinct patents associated with these drugs. Some of the drugs (56) did not 
have any listed patents. Our analysis uses the 430 drugs with at least one patent. 
Determining the earliest priority filing date for each drug 
We determined the priority date for each of the 1776 patents [4] using information from the 
Derwent World Patents Index [5]. For three patents which Derwent was missing 
information, we used information from the U.S. Patent and Trademark Office instead [6]. 
Drugs can have multiple patents. These typically include patents on the base molecule, on 
alternative structural forms of the molecule (e.g. salts, esters, enantiomers, polymorphs), on 
compositions and formulations, and on uses. We are interested in the priority dates for the 
compound patents, typically the strongest patents, as discussed in the paper. We did not 
code each patent to determine if it is a compound patent or not, but rather assumed that the 
patent with the earliest priority date is a given drug’s compound patent [7]. 
Figure One relates a drug’s earliest priority year across all of its patents (which we can think 
of as the drug’s priority year) to its approval year, and shows what share of drugs have 
priority years before 1995 [8]. 
Determining which drugs in our sample acheived high sales 
Using a list of the top 200 drugs by U.S. sales compiled by Pharmacy Times [9], we determined 
which of the drugs in our sample were among the top 50 in sales in 2012 [10]. The 
Supplementary Table lists these drugs, along with their priority and approval years. 
 [1] http://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm 
[2] Hemphill and Sampat, 2013. “Archival Orange Book Patent Data.” Available from 
authors, on request. 
[3] http://www.fda.gov/downloads/Drugs/InformationOnDrugs/UCM163762.zip 
[4] In some cases patents have multiple priority applications. In such cases we use the earliest 
priority year. 
[5] http://thomsonreuters.com/en/products-services/intellectual-property/patent-research-
and-analysis/derwent-world-patents-index.html 
[6] http://patft.uspto.gov/netahtml/PTO/srchnum.htm. The patents for which we used 
Patent Office information instead of Derwent are 8529882, 7820671, and 7668730. 
[7] For a set of new molecular entities with first generic entry in the U.S. between 2000 and 
2010 (see Hemphill, C. Scott, and Bhaven N. Sampat, “Evergreening, patent challenges, and 
effective market life in pharmaceuticals,” Journal of Health Economics 31.2, 2012: 327-339) that 
had a compound patent, we calculated that the priority year of the compound patent was the 
earliest priority year (across all patents on the drug) 95 percent of the time. 
[8] We assume that patents with priority dates before 1995 are ineligible in India. While this 
appears to be the conventional view, some experts suggest that applications filed in India 
after 1995 but with priority dates of 1994 may be eligible. See e.g. http://www.i-mak.org/i-
mak-blog-updates/2007/10/3/pre-95-drugs-are-not-patentable-in-india-or-are-they.html 
and http://spicyip.com/2010/07/prioritising-pharmaceutical-patents-in.html. As a practical 
matter there are very few granted Indian pharmaceutical patents with priority dates before 
1995 http://www.ipindia.nic.in/iponew/Patent_PharmaProduct_2005_06_2009_10.pdf. If 
we use 1994 as our cut-off date our main results are unchanged. Specifically, with a 1995 cut-
off date 30 percent of the drugs approved between 1995 and 2013 have their earliest priority 
dates after the cut-off. With a 1994 cut-off the share is 33 percent. 
[9] http://www.pharmacytimes.com/publications/issue/2013/July2013/Top-200-Drugs-of-
2012 
[10] By definition, drugs approved in 2013 could not appear on this list, so this analysis is 
based on the subset of drugs approved until 2012. 
